American Century Companies Inc. Acquires 8,470 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

American Century Companies Inc. lifted its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 18.5% during the second quarter, HoldingsChannel reports. The firm owned 54,323 shares of the company’s stock after acquiring an additional 8,470 shares during the quarter. American Century Companies Inc.’s holdings in Kodiak Sciences were worth $128,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Headlands Technologies LLC bought a new stake in Kodiak Sciences during the 1st quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences in the first quarter valued at approximately $68,000. Diversified Trust Co acquired a new position in shares of Kodiak Sciences in the first quarter valued at approximately $83,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Kodiak Sciences during the first quarter worth $86,000. Finally, Nan Fung Group Holdings Ltd raised its holdings in shares of Kodiak Sciences by 62.7% during the first quarter. Nan Fung Group Holdings Ltd now owns 31,922 shares of the company’s stock worth $168,000 after acquiring an additional 12,300 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Up 2.3 %

NASDAQ:KOD opened at $2.66 on Friday. The company has a market cap of $139.74 million, a P/E ratio of -0.60 and a beta of 2.34. Kodiak Sciences Inc. has a twelve month low of $1.37 and a twelve month high of $7.77. The business has a 50 day moving average price of $2.61 and a two-hundred day moving average price of $3.21.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Wednesday, August 14th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.01. As a group, analysts anticipate that Kodiak Sciences Inc. will post -3.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 target price on shares of Kodiak Sciences in a research note on Tuesday, September 24th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Kodiak Sciences has a consensus rating of “Hold” and an average price target of $5.00.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.